112 related articles for article (PubMed ID: 22819496)
1. A tissue factor targeted nanomedical system for thrombi-specific drug delivery.
Shi W; Mei H; Deng J; Chen C; Wang H; Guo T; Zhang B; Li L; Pang Z; Jiang X; Shen S; Hu Y
Biomaterials; 2012 Oct; 33(30):7643-54. PubMed ID: 22819496
[TBL] [Abstract][Full Text] [Related]
2. EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery.
Mei H; Shi W; Pang Z; Wang H; Lu W; Jiang X; Deng J; Guo T; Hu Y
Biomaterials; 2010 Jul; 31(21):5619-26. PubMed ID: 20413154
[TBL] [Abstract][Full Text] [Related]
3. The delivery of thrombi-specific nanoparticles incorporating oligonucleotides into injured cerebrovascular endothelium.
Shi W; Mei H; Deng J; Chen C; Wang H; Guo T; Zhang B; Pang Z; Jiang X; Wang X; Lei H; Hu Y
Biomaterials; 2013 May; 34(16):4128-4136. PubMed ID: 23465828
[TBL] [Abstract][Full Text] [Related]
4. A tissue factor-cascade-targeted strategy to tumor vasculature: a combination of EGFP-EGF1 conjugation nanoparticles with photodynamic therapy.
Shi W; Yin Y; Wang Y; Zhang B; Tan P; Jiang T; Mei H; Deng J; Wang H; Guo T; Pang Z; Hu Y
Oncotarget; 2017 May; 8(19):32212-32227. PubMed ID: 27793028
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight protamine-functionalized nanoparticles for drug delivery to the brain after intranasal administration.
Xia H; Gao X; Gu G; Liu Z; Zeng N; Hu Q; Song Q; Yao L; Pang Z; Jiang X; Chen J; Chen H
Biomaterials; 2011 Dec; 32(36):9888-98. PubMed ID: 21937105
[TBL] [Abstract][Full Text] [Related]
6. Solanum tuberosum lectin-conjugated PLGA nanoparticles for nose-to-brain delivery: in vivo and in vitro evaluations.
Chen J; Zhang C; Liu Q; Shao X; Feng C; Shen Y; Zhang Q; Jiang X
J Drug Target; 2012 Feb; 20(2):174-84. PubMed ID: 21992548
[TBL] [Abstract][Full Text] [Related]
7. EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma.
Zhang B; Wang H; Liao Z; Wang Y; Hu Y; Yang J; Shen S; Chen J; Mei H; Shi W; Hu Y; Pang Z; Jiang X
Biomaterials; 2014 Apr; 35(13):4133-45. PubMed ID: 24529623
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Antitumor Activity of EGFP-EGF1-Conjugated Nanoparticles by a Multitargeting Strategy.
Zhang B; Jiang T; Ling L; Cao Z; Zhao J; Tuo Y; She X; Shen S; Jiang X; Hu Y; Pang Z
ACS Appl Mater Interfaces; 2016 Apr; 8(14):8918-27. PubMed ID: 26890991
[TBL] [Abstract][Full Text] [Related]
9. A cascade targeting strategy for brain neuroglial cells employing nanoparticles modified with angiopep-2 peptide and EGFP-EGF1 protein.
Huile G; Shuaiqi P; Zhi Y; Shijie C; Chen C; Xinguo J; Shun S; Zhiqing P; Yu H
Biomaterials; 2011 Nov; 32(33):8669-75. PubMed ID: 21843903
[TBL] [Abstract][Full Text] [Related]
10. Binding of EGF1 domain peptide in coagulation factor VII with tissue factor and its implications for the triggering of coagulation.
Mei H; Hu Y; Wang H; Shi W; Deng J; Guo T
J Huazhong Univ Sci Technolog Med Sci; 2010 Feb; 30(1):42-7. PubMed ID: 20155454
[TBL] [Abstract][Full Text] [Related]
11. Early diagnosis of cerebral thrombosis by EGFP-EGF1 protein conjugated ferroferric oxide magnetic nanoparticles.
Hu Y; Li Z; Shi W; Yin Y; Mei H; Wang H; Guo T; Deng J; Yan H; Lu X
J Biomater Appl; 2019 Apr; 33(9):1195-1201. PubMed ID: 30646803
[TBL] [Abstract][Full Text] [Related]
12. Lactoferrin-modified PEG-co-PCL nanoparticles for enhanced brain delivery of NAP peptide following intranasal administration.
Liu Z; Jiang M; Kang T; Miao D; Gu G; Song Q; Yao L; Hu Q; Tu Y; Pang Z; Chen H; Jiang X; Gao X; Chen J
Biomaterials; 2013 May; 34(15):3870-81. PubMed ID: 23453061
[TBL] [Abstract][Full Text] [Related]
13. EGFP-EGF1-conjugated poly(lactic-co-glycolic acid) nanoparticles, a new diagnostic tool and drug carrier for atherosclerosis.
Wu Z; Chen C; Zhang B; Tang L; Shi W; Liao D; Di G; Davis JR; Wang H
Int J Nanomedicine; 2019; 14():2609-2618. PubMed ID: 31043777
[TBL] [Abstract][Full Text] [Related]
14. Brain targeting and toxicity study of odorranalectin-conjugated nanoparticles following intranasal administration.
Wen Z; Yan Z; He R; Pang Z; Guo L; Qian Y; Jiang X; Fang L
Drug Deliv; 2011 Nov; 18(8):555-61. PubMed ID: 21812752
[TBL] [Abstract][Full Text] [Related]
15. A tissue factor-cascade-targeted nanoparticle forsite-directed inducing thrombosis.
Jin W; Yin Y; Zhang B; Mei H; Wang H; Guo T; Shi W; Hu Y
J Biomater Appl; 2017 Sep; 32(3):342-348. PubMed ID: 28738734
[TBL] [Abstract][Full Text] [Related]
16. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy.
Gu G; Xia H; Hu Q; Liu Z; Jiang M; Kang T; Miao D; Tu Y; Pang Z; Song Q; Yao L; Chen H; Gao X; Chen J
Biomaterials; 2013 Jan; 34(1):196-208. PubMed ID: 23069707
[TBL] [Abstract][Full Text] [Related]
17. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson's disease.
Hu K; Shi Y; Jiang W; Han J; Huang S; Jiang X
Int J Pharm; 2011 Aug; 415(1-2):273-83. PubMed ID: 21651967
[TBL] [Abstract][Full Text] [Related]
18. Brain-targeted delivery of paclitaxel using glutathione-coated nanoparticles for brain cancers.
Geldenhuys W; Mbimba T; Bui T; Harrison K; Sutariya V
J Drug Target; 2011 Nov; 19(9):837-45. PubMed ID: 21692650
[TBL] [Abstract][Full Text] [Related]
19. Concanavalin A-conjugated poly(ethylene glycol)-poly(lactic acid) nanoparticles for intranasal drug delivery to the cervical lymph nodes.
Shao X; Liu Q; Zhang C; Zheng X; Chen J; Zha Y; Qian Y; Zhang X; Zhang Q; Jiang X
J Microencapsul; 2013; 30(8):780-6. PubMed ID: 23631383
[TBL] [Abstract][Full Text] [Related]
20. [Expression of fusion protein encoding EGFP-EGF1 of rat coagulation factor VII and its binding function].
May H; Hu Y; Zhang YH; Wang HF; Fang J; Guo T; Wei WN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):181-4. PubMed ID: 18315926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]